SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artŪculo

TORREGROSA, José V. et al. Tratamiento eficaz de la arteriolopatía urémica calcificante con bifosfonatos. Nefrología (Madr.) [online]. 2012, vol.32, n.3, pp.329-334. ISSN 0211-6995.

    1. Rogers NM, Coates PT. Calcific Uraemic Arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008;17:629-34. [ Links ]

    2. Llach F. The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant 2001;16:448-51. [ Links ]

    3. Price PA, Faus SA, Williamson MK. Biphosphonates alendronate and ibandronate inhibit artery calcification at dose comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001;21:817-24. [ Links ]

    4. Pallure V, Comte C, Leray-Mouragues H, Dereure O. Cinacalcet as first-line treatment for calciphylaxis. Acta Derm Venereol 2008;88:62-3. [ Links ]

    5. Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ. Proximal calciphylaxis treated with calcimimetic "cinacalcet". Nephrol Dial Transplant 2008;23:387-9. [ Links ]

    6. Kyritsis I, Gombou A, Griveas I, Agroyannis I, Retsa K, Agroyannis B. Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism. Int J Artif Organs 2008;31:742-4. [ Links ]

    7. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy in the treatment of calcific uremic arteriolopathy, a case series. J Nephrol 2002;15:676-80. [ Links ]

    8. Sood AR, Wazny LD, Raymond CB, Leung K, Komenda P. Sodium thiosulfate-based treatment in calcific uremic arteriolopathy: a consecutive case series. Clin Nephrol 2011;75:8-15. [ Links ]

    9. Hanafusa T, Yamaguchi Y, Tani M. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 2007;6:1021-25. [ Links ]

    10. Schliep S, Schuler G, Kiesewetter F. Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol 2008;18:554-6. [ Links ]

    11. Monney P, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004;19:2130-2. [ Links ]

    12. Da Costa JB, Da Costa AG, Gomes MM. Pamidronate as a treatment option in calciphylaxis. J Eur Acad Dermatol Venereol 2008;22:1128-30. [ Links ]

    13. Shiraishi N, Kitamura K, Miyoshi T, Adach M, Kohda Y, Nonoguchi H, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006;48:151-4. [ Links ]

    14. Meyer JL. Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 1984;231:1-8. [ Links ]

    15. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathologic calcification in vivo. Science 1969;165:1264-6. [ Links ]

    16. Schibler D, Russell GG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci 1968;35:363-72. [ Links ]

    17. Musso CG, Enz PA, Guelman R, Mombelli C. Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate. Perit Dial Int 2006;26:717-8. [ Links ]

    18. Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006;70:1577-83. [ Links ]

    19. Cecchini MG, Felix R, Fleisch H, Cooper PH. Effects of bisphosphonates on proliferation and viability of mouse bone marrow derived macrophages. J Bone Miner Res 1987;2:135-42. [ Links ]

    20. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916-22. [ Links ]

    21. Miller S, Vernon-Roberts E, McClure J. Cutaneous calciphylactic reactions in the mouse and the rat and the effects of diphosphonates on the reaction in the rat. J Pathol 1984;142:7-13. [ Links ]

    22. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106. [ Links ]

    23. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78. [ Links ]

    24. Viereck V, Emons G, Lauck VM, Frosch KH, Blaschke S, GrŁndker C, et al. Bisphosphonate pamidronate and zoledronic acid stimulate osteoprotegerin production by human osteoblasts. Biochem Biophys Res Commun 2002;291:680-6. [ Links ]

    25. Von Moos R, Caspar CB, Steiner R, Angst R, Inauen R, Schmieding K, et al. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. Onkologie 2010;33:447-50. [ Links ]